Cholera Vaccines Market - By Product (Dukoral, Vaxchora, Euvichol/Euvichol-Plus), End-user (Public, Private) – Global Forecast (2024 – 2032)

Cholera Vaccines Market Size

Cholera Vaccines Market size was valued at USD 89.4 million in 2023 and is estimated to grow at 8.4% CAGR from 2024 to 2032, due to the growing global burden of cholera outbreak, especially in areas with insufficient water and sanitation infrastructure.
 

For instance, according to the World Health Organization (WHO), there are 1.4 to 4.3 million cholera cases and up to 143,000 deaths annually, with a disproportionate burden in Africa and South Asia. This significant impact emphasized the urgent need for effective vaccination programs and prevention strategies, thereby expanding the market growth.
 

Additionally, growing awareness and initiatives by governments and international organizations to implement mass vaccination campaigns has fostered the market demand. Furthermore, the rising travel to endemic areas also boosts demand for cholera vaccines, as does the development of more accessible and affordable travel vaccine formulations, which enhance immunization efforts and market penetration.
 

Cholera vaccines are biological preparations used to provide active immunity against cholera, an acute diarrheal disease caused by the bacterium Vibrio cholerae. These vaccines are designed to stimulate the body's immune response to prevent the onset of the disease upon exposure to the pathogen.
 

Cholera Vaccines Market Trends

The growing government and organizations support & initiatives tend to propel the market growth by primarily facilitating mass vaccination campaigns particularly in high-risk areas to enhance the accessibility and distribution of cholera vaccines to address global needs. These collaborative efforts aimed to raise public awareness pertaining to the importance of cholera immunization, while also providing essential funding, technical assistance, and resources to enable the effective implementation of vaccination programs in underdeveloped areas, thereby driving the market demand.
 

• For instance, in March 2023, the WHO and the United Nations Children’s Fund (UNICEF) in collaboration with health authorities, the Syria Immunization Group (SIG), and Gavi, the Vaccine Alliance, launched a cholera vaccination campaign in earthquake-affected areas of northwest Syria. The campaign administered 1.7 million doses of cholera vaccine to protect Syrians over the age of one. This collaborative effort aimed at addressing public health crises, providing preventive measures against cholera in disaster-stricken regions, thereby bolstering the market demand.
   

Moreover, increasing research funding, and strategic approaches by key players focusing on the development, production, and distribution of cholera vaccines to vulnerable populations explore significant market opportunities.
 

Cholera Vaccines Market Analysis

Based on the product, the market is categorized as Dukoral, Vaxchora, Euvichol/Euvichol-Plus, and other products. The Euvichol/Euvichol-Plus product segment is set to lead the market, accounting for the largest revenue of USD 40.4 million in 2023, anticipating its dominance throughout the forecast period with a CAGR of 8.2%.
 

• Euvichol and Euvichol-Plus vaccines are in high demand and widely adopted for mass campaigns due to their effectiveness, ease of administration, and affordability. These oral cholera vaccines are favored for large-scale immunization efforts, particularly in regions prone to cholera outbreaks. Therefore, their proven track record in preventing cholera, coupled with support from global health organizations and governments will drive the market demand.

Based on end-user, the cholera vaccines market is classified into Public and private. The public segment holds the largest market share of 80.8% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• These healthcare facilities are primary points of contact for patients, making them essential for widespread vaccine distribution and administration. In January 2024, Zimbabwe launched a cholera vaccination campaign on Monday to immunize over 2 million people against the waterborne disease, aiming to curb an ongoing outbreak that has claimed hundreds of lives since last year. The campaign, supported by UNICEF and the WHO, will distribute a total of 2.3 million vaccine doses across 29 severely affected districts. This collaborative effort and government support aimed to address the global concern of cholera surging the need for vaccines.
   
• Therefore, public health campaigns and collaborate with government and international organizations to conduct mass vaccination drives significantly boosting the cholera vaccine market.

Canada dominated the North American cholera vaccines market accounting for USD 19.3 million in 2023 and is anticipated to show considerable growth over the analysis period.
 

• Canada's prominence was attributed to its comprehensive healthcare system, proactive public health policies, and high vaccination coverage. The country's stringent regulatory standards ensure the safety and efficacy of vaccines, fostering confidence among healthcare providers and the public.
   
• Additionally, Canada's strategic partnerships with vaccine manufacturers and international health organizations facilitate timely access to vaccines and support for nationwide immunization campaigns. These factors collectively enhance Canada's prominence in driving demand for cholera vaccines in the North American region.
   

The UK exhibited a high growth potential in the European cholera vaccines market.
 

• The UK government supports public health initiatives and provides funding for vaccine research and immunization programs. This commitment enhanced the country’s capacity to contribute significantly to the cholera vaccine market.
   
• Further, the country's collaboration with international organizations such as the WHO and Gavi plays a pivotal role in global cholera vaccination efforts. These partnerships enhance the UK's influence in the European cholera vaccine market.
   

The Asia Pacific leads the cholera vaccines market with a share of 41.5% in 2023 poised to grow with a CAGR of 8.7%.
 

• The high incidence of cholera outbreaks in Asia Pacific countries is driven by inadequate sanitation and water infrastructure. This situation fuels the demand for effective vaccination programs.
   
• For instance, according to the European Centre for Disease Prevention and Control (ECDC), from April 15, 2024, to May 30, 2024, 449 new cholera cases have been reported. Since January 1, 2024, a total of 1,769 cases, including four deaths, have been documented. In contrast, by May 19, 2023, 616 cases were reported. This significant increase highlighted the growing urgency for effective cholera prevention and control measures.
   
• Therefore, the strong governmental efforts to combat cholera, including mass vaccination campaigns and public health initiatives, contribute significantly to the region’s market growth.
   

Cholera Vaccines Market Share

The cholera vaccine market is fiercely competitive with numerous pharmaceutical and biotech companies vying for dominance. These companies are at the forefront of developing cutting-edge vaccine formulations, boosting production capabilities, and extending their global distribution networks. They strategically collaborate with research institutions and international bodies to strengthen research and development initiatives and expedite regulatory approvals. Additionally, significant investments in advanced vaccine technologies underscore their commitment to meeting the increasing demand for efficient cholera prevention measures in high-risk areas globally.
 

Cholera Vaccines Market Companies

The company profile section include both companies that have commercial drug available in market as well as those that are onto clinical phase development. Few of the prominent players operating in the cholera vaccines industry include:

• Bavarian Nordic A/S
• Bharat Biotech
• Biological E
• EuBiologics Co. Ltd.
• Hilleman Laboratories 
• Incepta Pharmaceuticals Ltd.
• Shantha Biotechnics (Sanofi)
• Vabiotech
• Valneva Sweden AB
   

Cholera Vaccines Industry News:

• In December 2023, Health authorities in Congo, alongside international health partners, initiated a cholera vaccination campaign aimed at vaccinating over 5 million residents across four provinces. The launch of this extensive campaign using oral vaccines in targeted provinces will safeguard a substantial number of vulnerable individuals and is vital in halting the disease's spread to other susceptible regions. This vaccination effort represented a critical step in controlling cholera outbreaks, demonstrating proactive measures to protect public health.
   
• In August 2023, GC Biopharma and Eubiologics signed a memorandum of understanding (MOU) for the co-production of Euvichol, an oral cholera vaccine. The agreement outlines cooperation to ensure a successful supply of the vaccine, with Eubiologics handling bulk vaccine production and GC Biopharma responsible for packaging, including vial bottling. This partnership aimed to strengthen production capabilities and enhance the distribution of Euvichol to meet global health needs effectively.
   

The cholera vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Dukoral
• Vaxchora
• Euvichol/Euvichol-Plus
• Other products

Market, By End-user

• Public
• Private

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • France
  • Spain
  • Netherlands
  • Belgium
  • Croatia
  • Rest of Europe
• Asia Pacific
  • India
  • Bangladesh
  • Pakistan
  • Philippines
  • Rest of Asia Pacific
• Latin America
  • Columbia
  • Peru
  • Chile
  • Rest of Latin America
• Middle East and Africa
  • Syria
  • Uganda
  • Yemen
  • Kenya
  • Zimbabwe
  • Rest of Middle East and Africa